CA2462443A1 - Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease - Google Patents

Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease Download PDF

Info

Publication number
CA2462443A1
CA2462443A1 CA002462443A CA2462443A CA2462443A1 CA 2462443 A1 CA2462443 A1 CA 2462443A1 CA 002462443 A CA002462443 A CA 002462443A CA 2462443 A CA2462443 A CA 2462443A CA 2462443 A1 CA2462443 A1 CA 2462443A1
Authority
CA
Canada
Prior art keywords
peptide
inhibitor
seq
camkii
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002462443A
Other languages
English (en)
French (fr)
Inventor
Mark Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2462443A1 publication Critical patent/CA2462443A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
CA002462443A 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease Abandoned CA2462443A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32657601P 2001-10-01 2001-10-01
US60/326,576 2001-10-01
US32801001P 2001-10-08 2001-10-08
US60/328,010 2001-10-08
PCT/US2002/031496 WO2003029428A2 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Publications (1)

Publication Number Publication Date
CA2462443A1 true CA2462443A1 (en) 2003-04-10

Family

ID=26985461

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002462443A Abandoned CA2462443A1 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Country Status (14)

Country Link
US (2) US7320959B2 (enExample)
EP (1) EP1439849A4 (enExample)
JP (1) JP2005504829A (enExample)
KR (1) KR20040045041A (enExample)
CN (1) CN1599622A (enExample)
AU (1) AU2002341938B2 (enExample)
BR (1) BR0213043A (enExample)
CA (1) CA2462443A1 (enExample)
IL (1) IL161231A0 (enExample)
MX (1) MXPA04003040A (enExample)
NO (1) NO20041331L (enExample)
NZ (1) NZ532327A (enExample)
PL (1) PL369104A1 (enExample)
WO (1) WO2003029428A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255121A1 (en) * 2004-11-02 2008-10-16 Dainippon Sumitomo Pharma Co., Ltd. Combination Drug for Treating Autoimmune Disease
CN107402307A (zh) * 2008-04-09 2017-11-28 B.R.A.H.M.S 有限公司 用于预测受损峰值耗氧量的内皮素1原
US8841423B2 (en) * 2008-04-28 2014-09-23 University Of Iowa Research Foundation Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
US20090275514A1 (en) * 2008-05-01 2009-11-05 Anderson Mark E Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation
WO2010135676A1 (en) * 2009-05-22 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Engineered biological pacemakers
US8440656B2 (en) * 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
EP3603658B1 (en) 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
CN105517549B (zh) 2013-03-06 2018-11-23 阿略斯泰罗斯医疗公司 CaMKII抑制剂和其用途
DE102014201651A1 (de) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen
CA2960101C (en) 2014-09-05 2024-05-21 Allosteros Therapeutics, Inc. Substituted carboline derivative and compositions thereof useful as camkii inhibitors
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
CN112972447B (zh) * 2021-03-02 2022-09-23 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) * 1968-10-17 1970-08-24
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JP2001509808A (ja) * 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
JP2963986B2 (ja) * 1997-11-19 1999-10-18 工業技術院長 カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤

Also Published As

Publication number Publication date
EP1439849A2 (en) 2004-07-28
BR0213043A (pt) 2004-10-05
US7632815B2 (en) 2009-12-15
NZ532327A (en) 2005-10-28
AU2002341938B2 (en) 2007-08-30
US20090011989A1 (en) 2009-01-08
NO20041331D0 (no) 2004-03-31
WO2003029428A8 (en) 2004-04-22
US20040266675A1 (en) 2004-12-30
NO20041331L (no) 2004-05-28
CN1599622A (zh) 2005-03-23
US7320959B2 (en) 2008-01-22
WO2003029428A3 (en) 2003-10-30
WO2003029428A2 (en) 2003-04-10
PL369104A1 (en) 2005-04-18
MXPA04003040A (es) 2004-07-15
EP1439849A4 (en) 2005-09-28
JP2005504829A (ja) 2005-02-17
KR20040045041A (ko) 2004-05-31
IL161231A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
US7632815B2 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
AU2002337811A1 (en) Adjustable child support structure with accessories
WO2003028507A2 (en) Adjustable child support structure with accessories
EP1420800B1 (en) Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity
US20090022729A1 (en) Methods and compositions for treating cardiac dysfunctions
US7208572B2 (en) Leptin-related peptides
AU2002341938A1 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
Jehle et al. A non-peptide angiotensin II type 2 receptor agonist does not attenuate post-myocardial infarction left ventricular remodeling in mice
JP2013177394A (ja) 抗β１アドレナリン受容体抗体を阻害する手段
JP2002528512A (ja) 心臓病及び心不全の治療のためのホスホランバン活性の阻害方法
JP2001515857A (ja) 細胞活性を調節する方法
Gulati et al. Characteristics of endothelin receptors in the central nervous system of spontaneously hypertensive rats
US20060281670A1 (en) Compositions and methods for modulating angiogenesis
US20040203087A1 (en) Inhibitors of the inositol polyphosphate 5-phosphatase SHIP2 molecule
KR102785286B1 (ko) 특발성 폐 섬유증의 약물 표적
US9527889B2 (en) RFamide-related peptides and methods thereof
AU2007237240A1 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
NZ541833A (en) Use of calmodulin kinase II inhibitors, mainly SEQ ID NO:4, to treat myocardial dysfunction in structural heart disease
US9993516B2 (en) Treatment of left ventricular non-compaction and dilated cardiomyopathy by inhibiting melanocortin receptor four
CN101130069A (zh) 用钙调蛋白激酶ii抑制剂治疗结构性心脏病中的心肌功能障碍
Larsen et al. Neuropeptide Y messenger ribonucleic acid in the magnocellular hypothalamo-neurohypophysial system of the rat is increased during osmotic stimulation
ZA200309727B (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor.
Bachmann et al. C‐type natriuretic peptide induces inotropic and lusitropic effects in human 3D‐engineered cardiac tissue: Implications for the regulation of cardiac function in humans
AU2002317634B2 (en) Modulation of insulin-regulated aminopeptidase (IRAP)/Angiotensin IV (AT4) receptor activity
US20160095837A1 (en) Modulation of mitochondrial calcium uniporter activity for treating and preventing arrhythmias

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued